Biomarkers of Progression and Risk Stratification in Asymptomatic Waldenström Macroglobulinemia

Mark Bustoros; Caitlin Gribbin; Jorge J Castillo; Richard Furman

doi:10.1016/j.hoc.2023.06.012

Biomarkers of Progression and Risk Stratification in Asymptomatic Waldenström Macroglobulinemia

Hematol Oncol Clin North Am. 2023 Aug;37(4S):e1-e13. doi: 10.1016/j.hoc.2023.06.012. Epub 2023 Aug 12.

Authors

Mark Bustoros¹, Caitlin Gribbin², Jorge J Castillo³, Richard Furman²

Affiliations

¹ Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, NewYork-Presbyterian Hospital, New York, NY, USA. Electronic address: mab4033@med.cornell.edu.
² Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, NewYork-Presbyterian Hospital, New York, NY, USA.
³ Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA.

PMID: 37574332
DOI: 10.1016/j.hoc.2023.06.012

Abstract

Waldenström macroglobulinemia is an indolent IgM-secreting B-cell lymphoplasmacytic lymphoma that is preceded by an asymptomatic stage. Clinical and molecular features have been used in risk models to predict progression rates in different asymptomatic subgroups. Risk models used both disease-specific and nonspecific biomarkers for asymptomatic patients. Recently, models that incorporate continuous variables rather than distinct cutoffs have emerged to more accurately predict the risk of progression. Integrating genetic alterations to the clinical models is a promising approach that could improve risk stratification and management of asymptomatic patients.

Keywords: Asymptomatic WM; Monoclonal gammopathy of undetermined significance (MGUS); Risk stratification; Smoldering WM; Waldenström macroglobulinemia.

Publication types

Review